Cellectis S.A. (NASDAQ:CLLS) Receives Average Rating of “Hold” from Brokerages

Cellectis S.A. (NASDAQ:CLLSGet Rating) has been assigned a consensus rating of “Hold” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $22.25.

CLLS has been the topic of several research reports. StockNews.com raised shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research lowered shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Thursday, January 6th. Finally, Wells Fargo & Company lowered shares of Cellectis from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $39.00 to $16.00 in a report on Thursday, January 6th.

A number of hedge funds have recently added to or reduced their stakes in CLLS. Long Focus Capital Management LLC purchased a new position in Cellectis in the 4th quarter worth approximately $9,390,000. 683 Capital Management LLC grew its stake in Cellectis by 488.7% in the 4th quarter. 683 Capital Management LLC now owns 352,638 shares of the biotechnology company’s stock worth $2,863,000 after buying an additional 292,738 shares in the last quarter. Capital International Investors boosted its stake in shares of Cellectis by 18.9% in the 4th quarter. Capital International Investors now owns 1,592,054 shares of the biotechnology company’s stock valued at $12,927,000 after purchasing an additional 252,718 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Cellectis in the 3rd quarter valued at $2,212,000. Finally, Legal & General Group Plc boosted its stake in shares of Cellectis by 55.5% in the 4th quarter. Legal & General Group Plc now owns 337,201 shares of the biotechnology company’s stock valued at $2,738,000 after purchasing an additional 120,369 shares in the last quarter. 39.04% of the stock is owned by institutional investors and hedge funds.

NASDAQ CLLS opened at $3.64 on Friday. The company’s 50 day moving average is $4.23 and its 200-day moving average is $6.96. Cellectis has a 12-month low of $3.43 and a 12-month high of $19.68. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.08. The firm has a market cap of $165.59 million, a P/E ratio of -1.44 and a beta of 2.25.

Cellectis (NASDAQ:CLLSGet Rating) last posted its quarterly earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.50. Cellectis had a negative net margin of 170.26% and a negative return on equity of 41.88%. The company had revenue of $13.66 million for the quarter, compared to analyst estimates of $12.30 million. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. Equities analysts expect that Cellectis will post -2.37 EPS for the current year.

About Cellectis (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Featured Articles

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.